• Angiotensin II: From Mechanistic Insight to Translational Le

  2026-06-06

  This thought-leadership article explores Angiotensin II’s molecular mechanisms—centered on Asp-Arg-Val-Tyr-Ile-His-Pro-Phe—and its strategic deployment in hypertension, vascular remodeling, and abdominal aortic aneurysm models. Integrating recent evidence on peptide-receptor interplay with advanced experimental protocols, we outline how translational researchers can harness Angiotensin II to bridge laboratory discovery with clinical innovation. The article highlights competitive advantages of APExBIO’s Angiotensin II, provides best-practice protocol guidance, and discusses the evolving landscape connecting cardiovascular research with emergent insights from viral pathogenesis.

• Spirocyclic POM Analogues Target MmpL3 for Tuberculosis Ther

  2026-06-05

  The study introduces spirocyclic phenyl oxazole methyl (POM) derivatives as potent inhibitors targeting MmpL3 in Mycobacterium tuberculosis, including drug-resistant strains. This work advances the search for novel anti-tubercular agents by identifying a new chemical class with favorable pharmacological properties and a validated mechanism.

• Anti Reverse Cap Analog: Workflow Advances for mRNA Translat

  2026-06-05

  Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, doubles synthetic mRNA translation by ensuring unidirectional capping—transforming mRNA therapeutics and gene expression studies. This guide breaks down protocol optimization, troubleshooting, and key insights from the latest reference-driven breakthroughs.

• Rapid In Vivo Screening of Chemotherapeutics in Pancreatic C

  2026-06-04

  This study introduces a concerted in vitro and in vivo screening platform using Rgs16::GFP as a reporter to accelerate identification of effective chemotherapeutic combinations for pancreatic ductal adenocarcinoma (PDA). The findings reveal that combining BET bromodomain and HDAC inhibition with gemcitabine enhances anti-tumor efficacy, providing a strategic advance for preclinical drug evaluation.

• Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO): Pract

  2026-06-04

  Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) provides broad-spectrum, EDTA-free protection against proteolytic degradation during protein extraction and analysis, especially where divalent cation compatibility is required. Use in workflows such as Western blot, Co-IP, and kinase assays; avoid scenarios needing metalloprotease inhibition by EDTA.

• Telmisartan in Cardiac Hypertrophy: Beyond AT1R Blockade

  2026-06-03

  Explore advanced scientific insights into Telmisartan, a potent angiotensin II receptor antagonist, and its mechanistic role in cardiovascular disease research. This article uncovers how Telmisartan's actions extend beyond blood pressure control, informing next-generation protocols for cardiac hypertrophy studies.

• Benzyl Quinolone Carboxylic Acid: Selective M1 Modulator Ins

  2026-06-03

  Benzyl Quinolone Carboxylic Acid (BQCA) is a selective positive allosteric modulator of the M1 muscarinic acetylcholine receptor. It enhances acetylcholine signaling with high specificity, supporting cognitive function studies and Alzheimer's disease research. Quantitative evidence demonstrates robust modulation of receptor pathways, with well-characterized pharmacological and workflow parameters.

• Mechanistic Excellence in mRNA Tracking: EZ Cap Cy5 Firefly

  2026-06-02

  This thought-leadership article explores how the integration of Cap1 capping, 5-moUTP modification, and Cy5 labeling in EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) advances the frontiers of mRNA delivery, dual-modality imaging, and translational research. We offer mechanistic insights, validation pathways, and strategic guidance for researchers navigating the evolving landscape of non-viral mRNA therapeutics.

• Quantifying Drug-Induced Fractional Killing via High-Through

  2026-06-02

  The referenced protocol by Inde et al. details a robust high-throughput microscopy workflow for quantifying fractional cell killing by anti-cancer compounds. This approach enables parallel comparison of multiple drug conditions and provides granular insights into population-level cell death dynamics—an important advance for apoptosis and kinase inhibitor research.

• Optimizing Protein Integrity with Protease Inhibitor Cocktai

  2026-06-01

  This article provides a scenario-driven, evidence-based guide for using the Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) (SKU K1008) to overcome real laboratory challenges in protein extraction, Western blotting, and cell-based assays. It details how this EDTA-free, DMSO-formulated cocktail ensures reproducible, cation-compatible workflows by preventing proteolytic degradation across a range of experimental needs. Readers will find protocol advice, vendor comparisons, and context from recent peer-reviewed research.

• Fosinopril Sodium in Experimental Hypertension Research

  2026-06-01

  Fosinopril sodium unlocks advanced modeling of cardiovascular and renal dynamics in preclinical studies. This article covers optimized workflows, troubleshooting, and protocol parameters for leveraging this potent ACE inhibitor, highlighting both technical nuances and translational impact.

• Mitochondrial NAD+ Deficiency Drives Aortic Aneurysm via Col

  2026-05-31

  This study identifies mitochondrial NAD+ deficiency in vascular smooth muscle cells as a causal factor in thoracic and abdominal aortic aneurysm, mechanistically linking impaired NAD+ salvage and transport to disrupted collagen III turnover. These findings highlight new molecular targets and provide a foundation for improved experimental models of aortic disease.

• Phosbind Acrylamide: Decoding Phosphorylation in Fungal Sign

  2026-05-30

  Explore how Phosbind Acrylamide empowers advanced protein phosphorylation analysis and unveils regulatory cascades in fungal metabolism. This article details the unique biochemical advantages of this phosphate-binding reagent and its impact on SDS-PAGE phosphorylation detection.

• miR-196a Drives EAC Aggressiveness via the MYC/TERT/NFκB Axi

  2026-05-29

  This study reveals that microRNA-196a (miR-196a) promotes aggressive behavior in esophageal adenocarcinoma (EAC) by activating the MYC/TERT/NFκB axis. The findings underscore c-Myc as a critical molecular node, highlighting new pathways for targeted cancer research and intervention.

• EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1

  2026-05-29

  EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) enables efficient amide bond formation during peptide synthesis, bioconjugation, and nucleotide coupling reactions in aqueous environments. It is strictly intended for in vitro laboratory workflows, as there is no evidence supporting in vivo or clinical use.

413 records 13/28 page Previous Next First page 上5页 1112131415 下5页 Last page